Health Care/Hospital

I-Mab Announces Upcoming Participation at January Conferences

SHANGHAI and GAITHERSBURG, MD., Dec. 31, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced its participation in the following conferences inJanuar...

2021-12-31 21:00 2871

GBB Closed the A Round Financing with Newly Joined FutureX Capital

HONG KONG, Dec. 31, 2021 /PRNewswire/ -- Great Bay Bio (GBB), an AI-enabled biotechnology company, announces the participation of FutureX Capital in its Series A round fundraising. Great Bay Bio finished A round financing of near USD 10 million o...

2021-12-31 20:44 3048

Zepp Health Provides Updates to Guidance and Share Repurchases

BEIJING, Dec. 31, 2021 /PRNewswire/ -- Zepp Health Corp.  (NYSE: ZEPP)  announced today an update to its guidance for the fourth quarter 2021, as well as an update to the progress of its share repurchase program. Due to greater than anticipated effects of Covid, including a more persistent worldw...

2021-12-31 20:00 5251

Landmark international innovation and entrepreneurship competition concludes in China's Chongqing with top prize worth 100 mln yuan

CHONGQING, China, Dec. 31, 2021 /PRNewswire/ -- Chongqing Liangjiang Collaborative Innovation Zone Mingyue Lake International Innovation and Entrepreneurship Competition concluded Thursday in Chongqing Liangjiang New Area. Contestants across the country leveraged their ideas and proposals to win ...

2021-12-31 19:15 2475

GenFleet Therapeutics Raises $75 Million in Series C Financing Led by Huagai Capital, to Advance Innovative Pipeline Highlighting Cutting-edge Therapies

SHANGHAI, Dec. 31, 2021 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company with a focus in cutting-edge therapies in oncology and immunology, today announced the completion of$75 million (~500 million RMB) series C financing. This round of financing is led by Huagai ...

2021-12-31 19:00 2058

China Medical System (867.HK)'s Latest MSCI ESG Rating Unchanged at AA, Leading the Industry Globally

HONG KONG, Dec. 30, 2021 /PRNewswire/ -- Recently, Morgan Stanley Capital International (MSCI), the world's largest index provider, has updated the Environmental, Social and Governance (ESG) rating of China Medical System Holdings Limited ("CMS" or the "Company").CMS's latest rating remains uncha...

2021-12-30 20:00 2344

Peijia Medical's New Milestone Asia's first successful clinical case using HighLife transseptal mitral valve replacement technology

SUZHOU, China, Dec. 30, 2021 /PRNewswire/ -- On December 22, 2021, the first clinical case using HighLife transseptal mitral valve replacement ("TSMVR") technology was successfully carried out inAsia. The implantation of Peijia's Highlife TSMVR system was performed by ProfessorMao Chen and his te...

2021-12-30 19:18 3160

Dada Group and Kimberly-Clark China Strengthen Partnership to Create New Growth of Healthcare Brands in On-demand Retail

SHANGHAI, Dec. 29, 2021 /PRNewswire/ -- Kimberly-Clark (China) Co., Ltd., the global leader in the personal care and hygiene industry, and Dada Group (Nasdaq: DADA), China's leading local on-demand delivery and retail platform, announced a plan to strengthen their strategic partnership. Philip KU...

2021-12-30 10:57 2563

iMEDISYNC UNVEILS WORLD'S FIRST INTEGRATED WIRELESS BRAIN EEG at CES 2022

SEOUL, South Korea, Dec. 29, 2021 /PRNewswire/ -- iMediSync, a leading AI-driven early detection and therapeutic platform for optimal brain health from Seoul, South Korea announced today that the company will showcase its comprehensive EEG solution (hardware + software + remote telehealth solution...

2021-12-30 00:00 2839

China Jo-Jo Drugstores Receives 2021 China ESG Golden Awards- Sustainability Award from Sina Finance

HANGZHOU, China, Dec. 29, 2021 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, today announced that the ...

2021-12-29 21:30 4341

SyMap Medical Ltd. Announces its Strategic Collaboration with Pythagoras Medical

SUZHOU, China, Dec. 29, 2021 /PRNewswire/ -- SyMap Medical Ltd (SyMap) announced its strategic collaboration with Pythagoras Medical. With this win-win collaboration, SyMap has full rights to utilize all assets of Pythagoras, including their Renal Nerve Mapping System (ConfidenHT™, CE Mark Appro...

2021-12-29 20:30 2189

EOFlow and Zihipp Announce Joint Venture for Development of Innovative Solutions for Treatment of Obesity & NASH

* Establishment of Joint Venture Company named SanPlena in the US * Drug-device combination of EOFlow's smart wearable drug delivery platform and novel peptide derivatives developed by a team led by Prof. SirStephen Bloom , world-renowned researcher in the field of obesity and metabolism at Imp...

2021-12-28 22:00 1957

Akeso's IL-17A MONOCLONAL ANTIBODY (GUMOKIMAB) COMPLETION OF PATIENT ENROLLMENT IN PHASE II CLINICAL TRIAL FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS

HONG KONG, Dec. 27, 2021 /PRNewswire/ -- Today, Akeso, Inc. (09926.HK) announces that Gumokimab  (IL-17A monoclonal antibody, AK111), an innovative drug independently developed by the Company for the treatment of active ankylosing spondylitis has been completed. Such clinical trial aims to evalua...

2021-12-28 12:30 2017

Regor Therapeutics Announces U.S. FDA Authorization to Conduct Regor's First-in-Human Clinical Trial with the Next Generation Targeted Inhibitor RGT-419B for Oncology

SHANGHAI, Dec. 27, 2021 /PRNewswire/ -- On December 23, Regor Therapeutics, a clinical-stage biotech company,announced authorization from the US Food and Drug Administration (FDA) to proceed with Regor's Phase 1 clinical development plans for RGT-419B. RGT-419B is a new generation CDK2/4/6, smal...

2021-12-28 09:00 1417

I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors

SHANGHAI and GAITHERSBURG, Md., Dec. 27, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced that the Center for Drug Evaluation (CDE) ofChina's National ...

2021-12-27 21:00 1941

Kintor Pharma Provides Update on One of its Three Multi-Regional Phase 3 Trials of Proxalutamide for COVID-19

SUZHOU, China, Dec. 27, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today provided an update on its multi-regional study of proxalutamide for the treatme...

2021-12-27 20:19 2400

Laekna Presents Vision and Strategy at NewYorkBIO/NYSE Emerging Company Showcase

SHANGHAI and WARREN, N.J., Dec. 24, 2021 /PRNewswire/ -- Laekna was invited by NewYorkBIO and the New York Stock Exchange (NYSE) to present, as an emerging biotech company at the "Emerging Company Showcase" that was held earlier this month inNew York. Dr. Guy Rosenthal, Vice President, Head of C...

2021-12-24 16:30 3700

Curocell, Breaks Ground on 'CAR-T Manufacturing GMP Facility'

DAEJEON, South Korea, Dec. 23, 2021 Curocell, currently on PhaseⅠCAR-T Therapy clinical trial withCRC01 (anbalcabtagene autoleucel) has recently broken ground for the new CAR-T Center in Dungok Residential & Industrial Area in Daejeon International Science & Business Belt.

2021-12-23 20:00 2180

Akeso's PCSK9 MONOCLONAL ANTIBODY (EBRONUCIMAB) EARLY COMPLETION OF PATIENT ENROLLMENT IN A PHASE III CLINICAL TRIAL FOR PRIMARY HYPERCHOLESTEROLEMIA AND MIXED HYPERLIPIDEMIA

HONG KONG, Dec. 22, 2021 /PRNewswire/ -- Today, Akeso, Inc. (09926.HK) announces that Ebronucimab (PCSK9 monoclonal antibody, research and development code: AK102), jointly developed by the Company and Dawnrays Biotechnology Capital (Asia) Ltd., completed patient enrollment early in a pivotal re...

2021-12-23 12:42 2298

Yiling Pharmaceutical's Patent Depression-resolving Drug Approved for Marketing in China

BEIJING, Dec. 22, 2021 /PRNewswire/ -- According to Yiling Pharmaceutical's notice onThursday (UTC+8), the Depression-resolving and Restlessness-relieving Capsules have been approved for marketing via the obtained Drug Registration Certificate issued byChina's National Medical Products Administra...

2021-12-23 11:59 1712
1 ... 180181182183184185186 ... 278